ATE312587T1 - Zusammenseztungen und verfahren zur behandlung von haarausfall unter verwendung von c16-c20 aromatischen tetrahydro-prostaglandinen - Google Patents

Zusammenseztungen und verfahren zur behandlung von haarausfall unter verwendung von c16-c20 aromatischen tetrahydro-prostaglandinen

Info

Publication number
ATE312587T1
ATE312587T1 AT01924517T AT01924517T ATE312587T1 AT E312587 T1 ATE312587 T1 AT E312587T1 AT 01924517 T AT01924517 T AT 01924517T AT 01924517 T AT01924517 T AT 01924517T AT E312587 T1 ATE312587 T1 AT E312587T1
Authority
AT
Austria
Prior art keywords
compositions
hair loss
prostaglandins
methods
treating hair
Prior art date
Application number
AT01924517T
Other languages
English (en)
Inventor
Mitchell Anthony Delong
John Mcmillan Mciver
Robert Scott Youngquist
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Application granted granted Critical
Publication of ATE312587T1 publication Critical patent/ATE312587T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/365—Hydroxycarboxylic acids; Ketocarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT01924517T 2000-03-31 2001-03-30 Zusammenseztungen und verfahren zur behandlung von haarausfall unter verwendung von c16-c20 aromatischen tetrahydro-prostaglandinen ATE312587T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19384600P 2000-03-31 2000-03-31
PCT/US2001/010368 WO2001074313A2 (en) 2000-03-31 2001-03-30 Compositions and methods for treating hair loss using c16 - c20 aromatic tetrahydro prostaglandins

Publications (1)

Publication Number Publication Date
ATE312587T1 true ATE312587T1 (de) 2005-12-15

Family

ID=22715257

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01924517T ATE312587T1 (de) 2000-03-31 2001-03-30 Zusammenseztungen und verfahren zur behandlung von haarausfall unter verwendung von c16-c20 aromatischen tetrahydro-prostaglandinen

Country Status (10)

Country Link
US (3) US20020037914A1 (de)
EP (1) EP1267803B1 (de)
JP (2) JP2003528897A (de)
CN (1) CN1206976C (de)
AT (1) ATE312587T1 (de)
AU (1) AU2001251166A1 (de)
CA (1) CA2401718C (de)
DE (1) DE60115869T2 (de)
ES (1) ES2254395T3 (de)
WO (1) WO2001074313A2 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2364948C (en) 1999-03-05 2011-04-26 Duke University C16 unsaturated fp-selective prostaglandins analogs
US20020146439A1 (en) * 2000-03-31 2002-10-10 Delong Mitchell Anthony Compositions and methods for treating hair loss using oximyl and hydroxylamino prostaglandins
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
US20020172693A1 (en) 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
US20020037914A1 (en) 2000-03-31 2002-03-28 Delong Mitchell Anthony Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins
WO2002089743A2 (en) 2001-05-09 2002-11-14 The Regents Of The University Of Michigan Use of compositions for treating rosacea
US7326717B2 (en) 2003-05-06 2008-02-05 L'oreal Pyrimidine n-oxide compounds for stimulating the growth of keratin fibers and/or reducing loss thereof
TWI495471B (zh) * 2003-08-12 2015-08-11 R Tech Ueno Ltd 促進毛髮生長之組成物及方法
US20060135609A1 (en) * 2004-10-21 2006-06-22 Duke University Ophthamological drugs
US20070254920A1 (en) * 2006-04-26 2007-11-01 Aerie Pharmaceuticals, Inc. Prodrug derivatives of acids using alcohols with homotopic hydroxy groups and methods for their preparation and use
FR2920309B1 (fr) 2007-08-28 2010-05-28 Galderma Res & Dev Utilisation de travoprost pour traiter la chute des cheveux
JP4891207B2 (ja) * 2007-11-27 2012-03-07 大洋香料株式会社 抗菌剤及びそれを含有する皮膚外用剤
US8455547B2 (en) * 2008-02-05 2013-06-04 Allergan, Inc. Substituted cyclopentanes having prostaglandin activity
US7964596B2 (en) * 2008-03-07 2011-06-21 Allergan, Inc. Therapeutic compounds
US8623918B2 (en) * 2008-10-29 2014-01-07 Novaer Holdings, Inc. Amino acid salts of prostaglandins
US8722739B2 (en) 2008-10-29 2014-05-13 Novaer Holdings, Inc. Amino acid salts of prostaglandins
WO2010064203A1 (en) 2008-12-02 2010-06-10 L'oreal Combination of reduced glutathione and amino acids for improving the quality of the hair in women
US20110293549A1 (en) 2009-02-03 2011-12-01 Athena Cosmetics, Inc. Composition, method and kit for enhancing hair
WO2011014649A1 (en) 2009-07-29 2011-02-03 Duke University Compositions and methods for inhibiting hair growth
FR2949052B1 (fr) 2009-08-13 2015-03-27 Oreal Procede de traitement cosmetique du cuir chevelu.
EP3421030A1 (de) 2009-11-09 2019-01-02 Allergan, Inc. Zusammensetzungen und verfahren zur stimulation des haarwuchses
WO2015065716A1 (en) 2013-10-15 2015-05-07 Case Western Reserve University Compositions and methods of modulating short-chain dehydrogenase activity
JP6203820B2 (ja) 2012-04-16 2017-09-27 ケース ウエスタン リザーブ ユニバーシティ １５−ｐｇｄｈ活性を調節する組成物および方法
US20150190383A1 (en) * 2014-01-08 2015-07-09 Aida Kalley Hair care composition with analgesic
US10561593B2 (en) 2015-12-28 2020-02-18 Johnson & Johnson Consumer Inc. Hair growth composition and method
EP3548035A4 (de) 2016-11-30 2020-07-22 Case Western Reserve University Kombinationen von 15-pgdh-inhibitoren mit corticosteroiden und/oder tnf-inhibitoren und verwendungen davon
AU2018215678A1 (en) 2017-02-06 2019-08-22 Board Of Regents Of The University Of Texas System Compositions and methods of modulating short-chain dehydrogenase activity
IL321451A (en) 2018-11-21 2025-08-01 Univ Case Western Reserve Compositions and methods of modulating short-chain dehydrogenase activity
EP3991734B1 (de) * 2019-06-28 2024-11-27 Gurus BioPharm Inc. Mittel zur behandlung der alopezie sowie zur förderung des haarwachstums
MX2022010258A (es) 2020-02-21 2023-01-24 Univ Case Western Reserve Composiciones y métodos para tratar la lesión renal.
CR20220654A (es) 2020-05-20 2023-08-24 Rodeo Therapeutics Corp Composiciones y métodos para modular la actividad de deshidrogenasas de cadena corta

Family Cites Families (299)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US13294A (en) 1855-07-17 Improved apparatus for cooling repeating fire-arms
US37914A (en) 1863-03-17 Improved automatic nose-bag
US146439A (en) 1874-01-13 Improvement in pruning-shears
US37913A (en) 1863-03-17 Improvement in sewing-machines
DE1617477U (de) 1950-09-27 1950-12-14 Heinrich Dressel Radhalter fuer raeder, beispielsweise fuer kinderwagen und kleinfahrzeuge.
US3839409A (en) * 1958-05-28 1974-10-01 Kemiska Inst Karolinska I Pge3 esters and alkanoates
US3776939A (en) * 1958-05-28 1973-12-04 S Bergstrom Dihydro-pgf1a
US3776938A (en) * 1958-05-28 1973-12-04 S Bergstrom Dihydro-pge1
US3069322A (en) * 1958-05-28 1962-12-18 Bergstrom Sune Pge and pgf
DE1801750U (de) 1959-07-07 1959-12-10 H L Wahrendorf Betonwerk Trog zur aufnahme des weichengestaenges von eisenbahngleisen.
US3382248A (en) * 1965-11-01 1968-05-07 Upjohn Co 6-amino-4, 5-di(substituted amino)-1, 2-dihydro-1-hydroxy-2-iminopyrimidines
US3524867A (en) * 1966-06-06 1970-08-18 Upjohn Co Process for producing cyclopenta (b)pyrans
US3435053A (en) * 1966-06-06 1969-03-25 Upjohn Co Cyclopenta(b)pyrans
US3538120A (en) 1967-05-22 1970-11-03 Ciba Geigy Corp Cyclopentyl-alkanoic acids
US3636120A (en) 1967-10-09 1972-01-18 Upjohn Co Prostaglandin e primary alcohols
GB1285371A (en) 1968-08-29 1972-08-16 Upjohn Co Improvements in or relating to therapeutic methods using prostaglandins
GB1251750A (de) 1968-11-12 1971-10-27
DE1910561A1 (de) 1969-03-01 1970-09-10 Herten Dr Med Kurt Mittel zur Verhuetung von Haarausfall
BE755555A (fr) * 1969-09-02 1971-03-01 Richardson Merrell Inc Derives de quinoxaline
US3882241A (en) * 1969-12-01 1975-05-06 Upjohn Co Use of prostaglandins E and F for prevention of pregnancy in humans
US3896156A (en) * 1970-06-30 1975-07-22 Upjohn Co Dihydroprostaglandin e, analogs
IT1012505B (it) 1970-09-28 1977-03-10 Imes C Spa Estratto di ricci di mare
BE791369A (fr) 1971-11-16 1973-05-14 American Cyanamid Co Cyanurates de tris-(meta-hydroxybenzyle) faisant l'objet d'un empechement sterique et utilisables comme anti-oxydants
US3798275A (en) 1972-04-05 1974-03-19 Ciba Geigy Corp Etherified mercapto-methoxyamines
US4304907A (en) 1972-05-10 1981-12-08 The Upjohn Company Bicyclo lactone intermediates for prostaglandin analogs
US4011262A (en) * 1972-07-13 1977-03-08 Pfizer Inc. 13,14-Dihydro-15-substituted-ω-pentanorprostaglandins of the two series
US3974213A (en) 1972-07-13 1976-08-10 Pfizer Inc. 13,14-Dihydro-15-substituted-ω-pentanorprostaglandins
US3882245A (en) * 1972-11-01 1975-05-06 Upjohn Co Use of prostaglandins in combating shock
US3984424A (en) 1972-11-08 1976-10-05 Pfizer Inc. P-biphenyl esters of 15-substituted-ω-pentanorprostaglandins
US4152527A (en) 1972-11-08 1979-05-01 Pfizer Inc. 15-Substituted-ω-pentanorprostaglandins
US4024179A (en) * 1972-11-08 1977-05-17 Pfizer Inc. Substituted ω-pentanorprostaglandins
DD118856A5 (de) 1972-11-08 1976-03-20
IL50310A (en) 1972-11-08 1977-08-31 Pfizer Dimethyl ketophosphonates
JPS49101356U (de) 1972-12-20 1974-08-31
JPS5320995Y2 (de) 1972-12-23 1978-06-02
JPS5720305B2 (de) 1973-02-28 1982-04-27
US3984455A (en) * 1973-07-16 1976-10-05 The Upjohn Company Prostaglandin E1 analogs
FR2239458A1 (en) 1973-07-31 1975-02-28 Aries Robert Prostaglandin amides - with antilipolytic, gonadotrophic, luteolytic, hypotensive and other activities associated with prostaglandins
DE2365101A1 (de) 1973-12-21 1975-07-10 Schering Ag Neue prostansaeurederivate und verfahren zu ihrer herstellung
US3931282A (en) 1974-02-21 1976-01-06 Syntex (U.S.A.) Inc. 11α-Hydroxymethyl prostaglandins
US3928588A (en) * 1974-02-22 1975-12-23 Upjohn Co Method of reducing the undesirable gastrointestinal effects of prostaglandin synthetase inhibitors
US4069885A (en) * 1974-03-27 1978-01-24 Klockner-Humboldt-Deutz Aktiengesellschaft Tractor-implement arrangement for establishing frictional engagement therebetween
DE2416193C2 (de) * 1974-04-03 1985-08-14 Hoechst Ag, 6230 Frankfurt Prostaglandin-Analoge, Verfahren zu ihrer Herstellung sowie ihre Verwendung als cytoprotektives Mittel
GB1458315A (en) 1974-04-22 1976-12-15 Ici Ltd Prostanoic acid derivatives
DE2460990A1 (de) 1974-12-21 1976-07-01 Hoechst Ag Neue prostaglandin-analoga und verfahren zu ihrer herstellung
GB1507211A (en) 1975-02-14 1978-04-12 Ono Pharmaceutical Co Prostaglandin analogues
US3934013A (en) 1975-02-21 1976-01-20 Syntex (U.S.A.) Inc. Pharmaceutical composition
US4217360A (en) * 1975-02-27 1980-08-12 Schering Aktiengesellschaft Novel 1,3-benzodioxaneprostanoic acid derivatives and process for the preparation thereof
GB1506817A (en) 1975-03-31 1978-04-12 Upjohn Co Prostaglandins
DE2517771A1 (de) * 1975-04-18 1976-10-28 Schering Ag Neue prostaglandin-acetylen-analoga und verfahren zu ihrer herstellung
GB1520522A (en) 1975-06-16 1978-08-09 Ono Pharmaceutical Co 16-methyleneprostaglandins
ES449162A1 (es) 1975-06-23 1977-12-16 Syntex Inc Un procedimiento para la preparacion de un compuesto racemi-co u 8r-antimerico.
US4005133A (en) 1975-10-14 1977-01-25 The Upjohn Company PGF2.sub.α, L-Arginine salt
US4128577A (en) 1975-12-29 1978-12-05 The Upjohn Company 15-Methyl- and 16-phenoxy-PGF2 α, amides
US4158667A (en) * 1976-02-04 1979-06-19 The Upjohn Company 6-Keto PGF analogs
US4139619A (en) * 1976-05-24 1979-02-13 The Upjohn Company 6-Amino-4-(substituted amino)-1,2-dihydro-1-hydroxy-2-iminopyrimidine, topical compositions and process for hair growth
US4596812A (en) * 1976-05-24 1986-06-24 The Upjohn Company Methods and solutions for treating male pattern alopecia
US4051238A (en) 1976-06-03 1977-09-27 The Upjohn Company Treatment of genital tract diseases of domestic animals with prostaglandins
US4268522A (en) 1976-06-14 1981-05-19 Pfizer Inc. 13,14-Dihydro-15-alkenyl- and 13,14-dihydro-15-alkynyl prostaglandins and analogs thereof
DE2635985A1 (de) * 1976-08-06 1978-02-09 Schering Ag Prostansaeurederivat und verfahren zu ihrer herstellung
DE2737807A1 (de) 1976-08-27 1978-03-09 Pfizer C tief 1 -p-biphenylester von omega-pentanorprostaglandinen
DE2737808A1 (de) 1976-08-27 1978-03-16 Pfizer 2-substituierte aryl-heterocyclische omega-pentanorprostaglandine
US4123441A (en) * 1976-09-22 1978-10-31 The Upjohn Company Enlarged-hetero-ring prostacyclin analogs
US4499293A (en) * 1976-09-22 1985-02-12 The Upjohn Company PGI2 Salts
US4089885A (en) * 1976-11-05 1978-05-16 American Home Products Corporation Prostaglandin derivatives
US4171331A (en) * 1978-06-05 1979-10-16 Miles Laboratories, Inc. 1 And 2-substituted analogues of certain prostaglandins
US4178457A (en) 1978-07-10 1979-12-11 Syntex (U.S.A.) Inc. (dl)-16-Phenoxy- and 16-substituted phenoxy-9-keto prostatrienoic acid derivatives and processes for the production thereof
US4206151A (en) 1978-12-21 1980-06-03 American Cyanamid Company 15-Deoxy-16-hydroxy-16-vinyl or cyclopropyl prostan-1-ols of the E, A and F series
US4311707A (en) * 1979-02-12 1982-01-19 American Cyanamid Company Process for topically producing cutaneous vasodilation for the treatment of vasospastic or ischemic conditions
GB2048254B (en) 1979-04-02 1983-05-25 Upjohn Co 19,20 -didehydro-19-hydroxy and 19-oxo-prostaglandin derivatives
US4225507A (en) * 1979-07-05 1980-09-30 The Upjohn Company 19-Hydroxy-19-methyl-PGI2 compounds
US4225508A (en) * 1979-07-05 1980-09-30 The Upjohn Company 19-Hydroxy-PGI2 compounds
US4296504A (en) 1980-07-07 1981-10-27 Lawson Daniel C Toilet seat lock
JPH0222226Y2 (de) 1981-02-04 1990-06-14
US4621100A (en) * 1981-09-25 1986-11-04 The Upjohn Company Treatment of osteoporosis with prostaglandins
CH656877A5 (de) 1981-11-27 1986-07-31 Erba Farmitalia Optisch aktive oder racemische prostaglandinderivate.
US4599353A (en) * 1982-05-03 1986-07-08 The Trustees Of Columbia University In The City Of New York Use of eicosanoids and their derivatives for treatment of ocular hypertension and glaucoma
US4912235A (en) 1983-12-22 1990-03-27 Syntex (U.S.A.) Inc. Processes and intermediates for making 16-phenoxy- and 16-substituted phenoxy-prostatrienoic acid derivatives and their stereoisomers
EP0187854A4 (de) 1984-07-13 1987-01-22 Gail S Bazzano Substituierte pyrimidinoxide, einsetzbar zur haarwachsanregung.
ES8607921A1 (es) 1984-07-31 1986-06-16 Syntex Inc Procedimiento para preparar derivados de acidos 11-sustitui-dos-16-fenoxi y 16-fenoxi sustituido-prostatrienoicos
JPS61126069A (ja) * 1984-11-21 1986-06-13 Res Dev Corp Of Japan プロスタグランジン誘導体
JPS61218510A (ja) * 1985-03-22 1986-09-29 Dai Ichi Seiyaku Co Ltd 毛髪用剤
US4757089A (en) 1985-06-14 1988-07-12 Massachusetts Eye And Ear Infirmary Increasing aqueous humor outflow
US5863948A (en) 1985-06-14 1999-01-26 Massachusetts Eye And Ear Infirmary Increasing aqueous humor outflow
US4704386A (en) * 1985-08-29 1987-11-03 G. D. Searle & Co. 8-chlorodibenz[b,f][1,4]oxazepine-10(11H)-carboxylic acid, 2-[(phenylsulfinyl-, and phenylsulfonyl)alkanoyl]hydrazides
US4883819A (en) 1986-07-31 1989-11-28 The Trustees Of Columbia University In The City Of New York Use of A, B and C prostaglandins and derivatives thereof to treat ocular hypertension and glaucoma
FI872552A7 (fi) * 1986-06-09 1987-12-10 American Cyanamid Co Paikallisesti käytettävä prostaglandiinikoostumus.
US4889845A (en) * 1986-06-09 1989-12-26 American Cyanamid Company Vehicle for topical application of pharmaceuticals
US5041439A (en) 1986-06-13 1991-08-20 The Procter & Gamble Company Penetrating topical pharmaceutical compositions
US5663203A (en) * 1986-09-11 1997-09-02 Schering Aktiengesellschaft Agents containing prostacyclin derivatives for topical application
US5500230A (en) * 1987-01-23 1996-03-19 The General Hospital Corporation Method for treatment of glaucoma with nitrogen containing guanylate cyclase activators
US5219885A (en) * 1987-02-16 1993-06-15 Froelich Juergen Prostaglandin E1 derivatives as pharmaceutically active agents, and pharmaceutical compositions containing these compounds, especially for transcutaneous administration
US4952581A (en) 1987-04-03 1990-08-28 The Trustees Of Columbia University In The City Of New York Use of a prostaglandin in combination with an adrenergic blocking agent for reduction of intraocular pressure
US5591887A (en) * 1987-04-30 1997-01-07 R-Tech Ueno, Ltd. Prostaglandins of the F series
GB8713747D0 (en) 1987-06-12 1987-07-15 Unilever Plc Skin treatment composition
ATE108330T1 (de) 1987-09-18 1994-07-15 R Tech Ueno Ltd Hypotensive okulare mittel.
US5166178B1 (en) 1987-09-18 1998-07-21 R Tech Ueno Ltd Ocular hypotensive agents
US6187813B1 (en) 1990-04-10 2001-02-13 Pharmacia & Upjohn Aktiebolag Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
US5321128A (en) 1988-09-06 1994-06-14 Kabi Pharmacia Ab Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
US5296504A (en) 1988-09-06 1994-03-22 Kabi Pharmacia Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
EP1348437A3 (de) 1988-09-06 2003-11-19 Pharmacia Aktiebolag Prostaglandinderivative zur Behandlung von Glaukoma oder okuläre Hypertension
US5194429A (en) * 1988-10-01 1993-03-16 K.K. Ueno Seiyaku Oyo Kenkyujo Ocular hypotensive agents
US4968812A (en) 1989-06-23 1990-11-06 Shell Oil Company Spirolactonelactams
JPH0737389B2 (ja) 1989-08-29 1995-04-26 久光製薬株式会社 プロスタグランジンｅ１含有の軟膏剤
CA1339132C (en) 1989-09-12 1997-07-29 Johan W. Stjernschantz Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
CA2030345C (en) 1989-11-22 1998-12-08 Ryuji Ueno Use of 15-keto-prostaglandin compound for improvement of encephalic function
JPH0627942Y2 (ja) 1989-12-14 1994-07-27 松下電器産業株式会社 ヒューズホルダー付コンデンサー
WO1991013207A1 (en) 1990-02-21 1991-09-05 Pulp And Paper Research Institute Of Canada POLY-β-HYDROXYALKANOATES FOR USE IN FIBRE CONSTRUCTS AND FILMS
TW224942B (de) 1990-04-04 1994-06-11 Adka Ueno Kk
US5063057A (en) * 1990-09-26 1991-11-05 Elizabeth Arden Co., Division Of Conopco, Inc. Cosmetic capsules
US5302617A (en) 1990-04-27 1994-04-12 Kabushikikaisha Ueno Seiyaku Oyo Kenkyuio Biochemical treatment with 15-dehydroxy-16-oxoprostaglandin compounds
DE4024347A1 (de) 1990-07-27 1992-01-30 Schering Ag Cyclopentanderivate, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung
JPH04300833A (ja) 1991-03-29 1992-10-23 Green Cross Corp:The プロスタグランジンｅ１　含有脂肪乳剤充填噴霧剤
US5378840A (en) * 1992-04-16 1995-01-03 G. D. Searle & Co. Substituted dibenzoxazepine compounds
US5312832A (en) 1991-05-17 1994-05-17 Allergan, Inc. Ocular hypotensive 2-decarboxyl-2-acylthioalkyl prostaglandin derivatives
US5288754A (en) * 1992-02-04 1994-02-22 Allergan, Inc. Polar C-1 esters of prostaglandins
US5641494A (en) * 1992-03-20 1997-06-24 Janssen Pharmaceutica N.V. Agent for regulating the greasiness of the skin
US5578643A (en) * 1992-05-20 1996-11-26 Loyola University Of Chicago Protective prostaglandins for use in conjunction with chemotherapeutic agents
US5422371A (en) * 1992-05-27 1995-06-06 Arch Development Corp. Methods and compositions for inhibiting 5α-reductase activity
JP3102141B2 (ja) * 1992-05-29 2000-10-23 東レ株式会社 養毛育毛剤
US5817694A (en) * 1992-06-08 1998-10-06 New Pharma International Corp. 16-methyl-11,16-dihydroxy-9-oxoprost-2,13-dien-1-oic acid and derivatives
US5409911A (en) 1992-09-11 1995-04-25 Merck & Co., Inc. Prostaglandin analog for treating osteoporosis
US5352708A (en) 1992-09-21 1994-10-04 Allergan, Inc. Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US5972991A (en) * 1992-09-21 1999-10-26 Allergan Cyclopentane heptan(ene) oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US5688819A (en) 1992-09-21 1997-11-18 Allergan Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US5834498A (en) * 1992-09-21 1998-11-10 Allergan Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
DE69311361T2 (de) 1992-10-13 1998-01-08 Alcon Lab Inc Zusammensetzungen zur behandlung von glaukoma die prostaglandine und clonidinderivate enthalten
US5332730A (en) 1992-10-16 1994-07-26 Allergan, Inc. Azido derivatives of cyclopentane heptanoic or heptenoic acid
US5340813A (en) * 1992-11-09 1994-08-23 Cell Therapeutics, Inc. Substituted aminoalkyl xanthine compounds
DE4238830A1 (de) * 1992-11-17 1994-05-19 Anton Felder Verfahren zum hydraulischen Verzweigen einer offenen Strömung sowie hydraulisch arbeitende Kanalverzweigung
US5670506A (en) * 1993-04-05 1997-09-23 Cell Therapeutics, Inc. Halogen, isothiocyanate or azide substituted xanthines
US5395932A (en) * 1993-04-30 1995-03-07 G. D. Searle & Co. 2,3-,4-,5-,6-,7-,8-,9- and/or 10-substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
US5985597A (en) * 1993-05-26 1999-11-16 Merck Frosst Canada, Inc. DNA encoding prostaglandin receptor EP1
US5869281A (en) * 1993-06-25 1999-02-09 Merck Frosst Canada Inc. DNA encoding prostaglandin receptor FP
ATE172471T1 (de) 1993-06-25 1998-11-15 Merck Frosst Canada Inc Prostaglandin rezeptor ep3 und kodierende dns
US5510383A (en) * 1993-08-03 1996-04-23 Alcon Laboratories, Inc. Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension
US5605814A (en) * 1993-08-31 1997-02-25 Merck Frosst Canada Inc. DNA encoding human prostaglandin receptor EP2
US5516652A (en) * 1993-10-06 1996-05-14 Merck Frosst Canada Inc. DNA encoding prostaglandin receptor IP
FR2711060B1 (fr) 1993-10-13 1995-11-17 Oreal Procédé pour modifier la pousse des poils et/ou des cheveux et compositions utilisables à cet effet.
SE9303444D0 (sv) * 1993-10-20 1993-10-20 Kabi Pharmacia Ab New use of prostaglandins
WO1995011033A1 (en) 1993-10-22 1995-04-27 Commonwealth Scientific And Industrial Research Organisation Polyoxometallates in the treatment of flavivirus infections
SE9303627D0 (sv) * 1993-11-03 1993-11-03 Kabi Pharmacia Ab Method and means for prevention of cataract
US5431881A (en) * 1993-12-10 1995-07-11 Palacios; Henry J. Treatment of hair loss and dermatological problems
JPH09506894A (ja) * 1993-12-20 1997-07-08 藤沢薬品工業株式会社 ４，５−ジアリールオキサゾール誘導体
US6124344A (en) 1993-12-28 2000-09-26 Allergan Sales, Inc. Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US5545665A (en) * 1993-12-28 1996-08-13 Allergan Cyclopentane(ene) heptenoic or heptanoic acids and derivatives thereof useful as therapeutic agents
US5458883A (en) 1994-01-12 1995-10-17 Duke University Method of treating disorders of the eye
US5462968A (en) 1994-01-19 1995-10-31 Allergan, Inc. EP2 -receptor agonists as agents for lowering intraocular pressure
ZA95627B (en) 1994-01-28 1995-10-05 Procter & Gamble Biodegradable copolymers and plastic articles comprising biodegradable copolymers
US5476372A (en) 1994-02-10 1995-12-19 Yang; Hsi-Kung Manual pump
SE9403158D0 (sv) * 1994-09-21 1994-09-21 Pharmacia Ab New use of prostaglandins
US5698733A (en) 1994-09-30 1997-12-16 Alcon Laboratories, Inc. Use of 9-deoxy prostaglandin derivatives to treat glaucoma
US5885974A (en) * 1994-12-06 1999-03-23 Michael M. Danielov Therapeutic methods utilizing naturally derived bio-active complexes and delivery systems therefor
EP0751126A4 (de) * 1995-01-06 1998-05-13 Toray Industries Benzokundensierte heterocyclen und deren verwendung
JP3064015B2 (ja) * 1995-01-26 2000-07-12 メルク フロスト カナダ アンド カンパニー プロスタグランジンレセプターｄｐ
US5885766A (en) * 1995-02-17 1999-03-23 Societe L'oreal S.A. Method of screening of substances for their effect on the expression of mediators of inflammation in a hair follicle
FR2730811B1 (fr) 1995-02-17 1997-03-21 Oreal Procede pour diagnostiquer et/ou suivre l'evolution d'un desordre capillaire et/ou mesurer l'efficacite d'un traitement applique pour combattre un desordre capillaire
DE69613693T2 (de) 1995-05-18 2002-05-16 Allergan Sales, Inc. 2-heteroarylalkenylderivate der cyclopentano-heptan(heptaen)säure als therapeutisches mittel zur behandlung des erhöhten augeninnendruckes
WO1998021180A1 (en) 1995-06-07 1998-05-22 Alcon Laboratories, Inc. Conformationally rigid aryl- or heteroaryl prostaglandins for use in glaucoma therapy
AU6017396A (en) * 1995-06-26 1997-01-30 Teijin Limited Prostaglandins and process for producing the same
TW401408B (en) 1995-07-21 2000-08-11 Fujisawa Pharmaceutical Co Heterocyclic compounds having prostaglandin I2 agonism
HUP9601442A3 (en) * 1995-07-25 1999-03-29 Panacea Biotec Ltd Nes antinflammatory and analgetic pharmaceutical compositions, containing nimesulid for transdermal use, and process for producing them
US5661178A (en) 1995-09-01 1997-08-26 Allergan Method for effecting vasodilation with (1,5-inter)aryl prostaglandin derivatives
US6251436B1 (en) 1995-09-29 2001-06-26 L.A.M. Pharmaceutical Corporation Drug preparations for treating sexual dysfunction
WO1997015319A1 (en) 1995-10-23 1997-05-01 Queen's University At Kingston Method and pharmaceutical composition for chondrostimulation with a prostaglandin (e.g. misoprostol) and tgf-beta, optionally in combination with igf-1
US6441047B2 (en) 1995-11-17 2002-08-27 Alcon Manufacturing Ltd.. Combination therapy for treating glaucoma
US5866602A (en) 1995-12-22 1999-02-02 Alcon Laboratories, Inc. Keto-substituted tetrahydrofuran analogs of prostaglandins as ocular hypotensives
US5814660A (en) 1995-12-22 1998-09-29 Alcon Laboratories, Inc. 9-oxa prostaglandin analogs as ocular hypotensives
AU1138097A (en) 1995-12-22 1997-07-17 Alcon Laboratories, Inc. Combinations of prostaglandins and miotics for lowering intraocular pressure
AU714272B2 (en) 1995-12-22 1999-12-23 Alcon Laboratories, Inc. Substituted tetrahydrofuran analogs of prostaglandins as ocular hypotensives
WO1997023225A1 (en) 1995-12-22 1997-07-03 Alcon Laboratories, Inc. Combinations of dp and fp type prostaglandins for lowering iop
AUPN814496A0 (en) 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer
US5703108A (en) * 1996-02-28 1997-12-30 Pfizer Inc. Bone deposition by certain prostaglandin agonists
US5741810A (en) 1996-02-29 1998-04-21 Allergan Cyclopentane heptan(ene)oic acid, 2- heteroarylalkenyl derivatives as therapeutic agents
US5658897A (en) * 1996-04-08 1997-08-19 Allergan Cyclopentane(ene) heptanoic or cyclopentane(ene) heptenoic acid, 2-hydrocarbyl phosphinyloxyalkyl or phosphonamidoalkyl as therapeutic agents
US5990168A (en) 1996-04-18 1999-11-23 Alberta Cancer Board Methods and compositions for the treatment of ataxia telangiectasia
JP3049593B2 (ja) * 1996-05-01 2000-06-05 株式会社ビメーク 育毛・養毛剤
AU3588797A (en) 1996-07-03 1998-01-21 Board Of Regents Of The University Of Oklahoma, The Enhancement of skin pigmentation by prostaglandins
US5792851A (en) * 1996-09-03 1998-08-11 Albert Einstin College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Human prostaglandin transporter
EP0930296B2 (de) 1996-09-17 2005-11-02 Asahi Glass Company Ltd. Fluorierte prostaglandinderivate und medikamente
US5827508A (en) 1996-09-27 1998-10-27 The Procter & Gamble Company Stable photoprotective compositions
JP3537274B2 (ja) 1996-10-29 2004-06-14 鐘淵化学工業株式会社 生分解性を有する積層体
JP2001504100A (ja) 1996-11-01 2001-03-27 アルコン・ラボラトリーズ・インコーポレーテッド 緑内障を治療するための炭酸脱水素酵素阻害剤とプロスタグランジンとの組合せの使用
US6649653B1 (en) 1996-11-12 2003-11-18 Alcon Manufacturing, Ltd. 15-fluoro prostaglandins as ocular hypotensives
WO1998020880A2 (en) 1996-11-12 1998-05-22 Alcon Laboratories, Inc. 11-halo prostaglandins for the treatment of glaucoma or ocular hypertension
US6353014B1 (en) 1996-11-12 2002-03-05 Alcon Laboratories, Inc. 15-ketal postaglandins for the treatment of glaucoma or ocular hypertension
EP0944593A2 (de) 1996-11-12 1999-09-29 Alcon Laboratories, Inc. $i(CIS)-$g(D)?4 ANALOGA VON PROSTAGLANDINEN ALS AUGENDRUCKSENKENDE MITTEL
TW523506B (en) 1996-12-18 2003-03-11 Ono Pharmaceutical Co Sulfonamide or carbamide derivatives and drugs containing the same as active ingredients
WO1998027976A1 (en) 1996-12-20 1998-07-02 Pfizer Inc. Prevention and treatment of skeletal disorder with ep2 receptor subtype selective prostaglandin e2 agonists
UA59384C2 (uk) 1996-12-20 2003-09-15 Пфайзер, Інк. Похідні сульфонамідів та амідів як агоністи простагландину, фармацевтична композиція та способи лікування на їх основі
JPH10265454A (ja) * 1997-01-27 1998-10-06 Ono Pharmaceut Co Ltd ３，７−ジチアプロスタン酸誘導体、それらの製造方法およびそれらを有効成分として含有する薬剤
ATE266397T1 (de) * 1997-02-04 2004-05-15 Murray A Johnstone Verfahren zur förderung des haarwuchses und entwicklung des haarsystems
NO317155B1 (no) * 1997-02-04 2004-08-30 Ono Pharmaceutical Co <omega>-cykloalkyl-prostagladin-E<N>2</N>-derivater
JP4044967B2 (ja) 1997-02-10 2008-02-06 小野薬品工業株式会社 １１，１５−ｏ−ジアルキルプロスタグランジンｅ誘導体、それらの製造方法およびそれらを有効成分として含有する薬剤
EP0925787A4 (de) 1997-02-27 1999-12-01 Toray Industries Arzneimittel zur verbesserung des lungkreislaufs
WO1998039293A2 (en) 1997-03-07 1998-09-11 Alcon Laboratories, Inc. 13-thia prostaglandins for use in glaucoma therapy
US6030959A (en) * 1997-04-04 2000-02-29 Monsanto Company Gastro-specific prodrugs
JP3217293B2 (ja) * 1997-04-17 2001-10-09 株式会社アールテック・ウエノ 発毛・育毛剤
CA2293325C (en) 1997-05-09 2008-09-02 The Mount Sinai School Of Medicine Of The City University Of New York 8-iso-prostaglandins for glaucoma therapy
WO1998053809A1 (en) 1997-05-30 1998-12-03 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
US6531485B2 (en) 1997-06-23 2003-03-11 Pfizer Inc. Prostaglandin agonists
SE9702706D0 (sv) 1997-07-11 1997-07-11 Pharmacia & Upjohn Ab Prostaglandin derivatives devoid of side-effects for the treatment of glaucoma
AU9374198A (en) 1997-09-08 1999-03-29 Idec Pharmaceuticals Corporation Methods for producing human antibodies in scid mice using dendritic cells
AU9307198A (en) 1997-09-08 1999-03-29 Abraham Pinter Hiv-1 gp120 v1/v2 domain epitopes capable of generating neutralizing antibo dies
US6066751A (en) 1997-09-09 2000-05-23 The Procter & Gamble Company Process for making epoxide intermediates
CA2302255C (en) 1997-09-09 2011-11-08 F. Hoffmann-La Roche Ag Fracture healing using pthrp analogs
ES2288766T3 (es) 1997-09-09 2008-01-16 Curis, Inc. Efectos sinergicos de morfogenes op/bmp y factores neurotroficos gdnf/ngf.
HUP0004436A3 (en) * 1997-09-09 2001-09-28 Procter & Gamble Aromatic c16-c20-substituted tetrahydro prostaglandins useful as fp agonists
CA2303800A1 (en) 1997-09-09 1999-03-18 Mark Walden Lundy Method of increasing bone volume using non-naturally-occurring fp selective agonists
SK3382000A3 (en) * 1997-09-09 2000-10-09 Procter & Gamble A compound having structure of aromatic substituted prostaglandins and its use for the treatment of bone disorders
EP1011709A4 (de) 1997-09-09 2003-06-18 Univ California Apoptosehemmung durch prosaposin rezeptoragonisten
SK3402000A3 (en) 1997-09-09 2000-12-11 Procter & Gamble Use of a substance primary activating the osteoblastic protein kinase c/intracellular calcium pathways of a subject
BR9811774A (pt) * 1997-09-09 2000-08-29 Procter & Gamble Tetraidroprostaglandinas aromáticas substituìdas por c16-c20 úteis como agonistas fp
AUPO907697A0 (en) 1997-09-09 1997-10-02 Day, Robert Edward Chemical supplementation of bone
AU9305898A (en) * 1997-09-09 1999-03-29 Procter & Gamble Company, The A process for making prostaglandin f analogs
ATE353014T1 (de) 1997-09-10 2007-02-15 Merial Ltd Verwendung von 9a-azaliden als antimikrobielle mittel für tiere
AU9312598A (en) 1997-09-10 1999-03-29 Allegheny University Of The Health Sciences Inhibitors of collagen assembly
CA2303410A1 (en) 1997-09-11 1999-03-18 The Government Of The United States Of America, As Represented By The Se Cretary Of The Department Of Health And Human Services Mucosal cytotoxic t lymphocyte responses
EP1011699B1 (de) 1997-09-11 2001-12-05 Purdue Research Foundation Durch galactosidase modifiziertes submucosales gewebe
JP2001515707A (ja) 1997-09-12 2001-09-25 スミスクライン・ビーチャム・コーポレイション 新規原核生物ポリヌクレオチド、ポリペプチドおよびそれらの使用
WO1999013881A1 (en) 1997-09-17 1999-03-25 Toray Industries, Inc. Cervical maturing agent
ATE253047T1 (de) 1997-09-19 2003-11-15 Shionogi & Co Verbindungen mit (2.2.1)bicyclischer molekülstruktur
UA67754C2 (uk) 1997-10-10 2004-07-15 Пфайзер, Інк. Агоністи простагландину, фармацевтична композиція на їх основі (варіанти), спосіб нарощення та збереження кісткової маси у хребетних та спосіб лікування (варіанти)
US6124314A (en) 1997-10-10 2000-09-26 Pfizer Inc. Osteoporosis compounds
AU740758B2 (en) 1997-10-28 2001-11-15 Vivus, Inc. Treatment of female sexual dysfunction
AUPP010397A0 (en) 1997-10-30 1997-11-20 Vaisman, Jakov Method and composition for treatment of sexual dysfunction
KR100638684B1 (ko) 1997-11-14 2006-10-27 유나이티드 세러퓨틱스 코오포레이션 말초 혈관 질환의 치료를 위한 9-데옥시-2',9-알파-메타노-3-옥사-4,5,6-트리노르-3,7-(1',3'-인터페닐렌)-13,14-디하이드로-프로스타글란딘 에프1의 용도
US5877211A (en) * 1997-11-21 1999-03-02 Allergan EP2 receptor agonists as neuroprotective agents for the eye
EP1059926A2 (de) 1997-12-18 2000-12-20 SCOTT, Nathan Earl Kombination, bestehend aus den prostaglandinen e2/f2-alpha, zur behandlung der impotenz und zur erhöhung der sexuelllen erregbarkeit
US6099870A (en) 1997-12-18 2000-08-08 Johnson & Johnson Consumer Companies, Inc. Methods for improving the health of hair and scalp
EP1040197A1 (de) 1997-12-22 2000-10-04 Unilever N.V. Verfahren zur ortsspezifischen integration von mehrfachkopien eines gens in einem schimmelpilz
WO1999032441A1 (en) 1997-12-22 1999-07-01 Alcon Laboratories, Inc. 13-oxa prostaglandins for the treatment of glaucoma and ocular hypertension
US5955575A (en) 1997-12-22 1999-09-21 Hopital Sainte-Justine Antagonists of G-protein-coupled receptor
ES2216336T3 (es) 1997-12-25 2004-10-16 Ono Pharmaceutical Co., Ltd. Derivados omega-cicloalquilos de la prostaglandina e2.
GB2330307A (en) 1998-02-07 1999-04-21 Glaxo Group Ltd EP4 Receptor antagonists as bone resorption inhibitors
EP1071648A2 (de) 1998-03-13 2001-01-31 Merck Frosst Canada &amp; Co. CARBONSÄUREN UND ACYLSULFONAMIDE, SOLCHE VERBINDUNGEN ENTHALTENDE Gemenge UND BEHANDLUNGSVERFAHREN
TR200002808T2 (tr) 1998-03-31 2001-01-22 The Procter & Gamble Company İlaç olarak yararlı C11 oksimil ve hidroksilamino prostaglandinleri
DE69925475T2 (de) 1998-03-31 2005-11-17 Duke University C11 oxymyl- und hydroxylamino-prostaglandine verwendbar als fp-agonisten
US6444840B1 (en) 1998-03-31 2002-09-03 The Procter & Gamble Co. C11 oxymyl and hydroxylamino prostaglandins useful as FP agonists
DE69912277T2 (de) 1998-05-25 2004-07-15 Taisho Pharmaceutical Co., Ltd. Prostaglandinderivate
US6458549B2 (en) 1998-06-11 2002-10-01 Winthrop-University Hospital Methods of diagnosing renal salt wasting syndrome and Alzheimer's disease and methods of treating the same
US5942545A (en) 1998-06-15 1999-08-24 Macrochem Corporation Composition and method for treating penile erectile dysfunction
US6187818B1 (en) 1998-06-17 2001-02-13 Pharmacia & Upjohn Company Prostaglandins formulation and process
US20010006979A1 (en) 1998-07-08 2001-07-05 Richard Stratton Method for treatment of fibrosis related diseases by the administration of prostacyclin derivatives
DE69922916T2 (de) 1998-07-14 2005-06-09 Alcon Manufacturing Ltd., Fort Worth Polypropylenbasierte behälter für prostaglandin-enthaltende produkte
TWI249520B (en) 1998-07-15 2006-02-21 Ono Pharmaceutical Co 5-Thia-omega-substituted phenyl prostaglandin E derivatives, method for producing the same and medicines containing the same as the active ingredient
CA2337349A1 (en) 1998-07-21 2000-02-03 Gerald S. Ponticello Ophthalmic compositions for treating ocular hypertension
EP1109546A1 (de) 1998-07-21 2001-06-27 Merck & Co., Inc. Ophthalmika zur behandlung der okularen hypertension
US6284234B1 (en) * 1998-08-04 2001-09-04 Johnson & Johnson Consumer Companies, Inc. Topical delivery systems for active agents
WO2000009557A1 (fr) 1998-08-12 2000-02-24 Kazusa Dna Research Institute Foundation Nouveau gene et nouvelle proteine pgth codee par ce gene
KR20010074981A (ko) 1998-09-14 2001-08-09 우에노 도시오 ω치환된 페닐프로스타그란딘 Ｅ 유도체 및 그 유도체를유효 성분으로 하는 약제
AUPP608898A0 (en) 1998-09-23 1998-10-15 Fujisawa Pharmaceutical Co., Ltd. New use of prostaglandin E2 antagonists
US6121253A (en) 1998-11-20 2000-09-19 Merck Frosst Canada & Co. Prostaglandin conjugates for treating or preventing bone disease
PT1157001E (pt) 1999-03-01 2004-10-29 Pfizer Prod Inc Acidos oxamicos e derivados como ligandos do receptor da tiroide
CA2364948C (en) 1999-03-05 2011-04-26 Duke University C16 unsaturated fp-selective prostaglandins analogs
ATE283256T1 (de) 1999-03-05 2004-12-15 Univ Duke C-16 ungesätigte fp-selektive prostaglandin analoge
US6894175B1 (en) 1999-08-04 2005-05-17 The Procter & Gamble Company 2-Decarboxy-2-phosphinico prostaglandin derivatives and methods for their preparation and use
IL147771A0 (en) 1999-08-04 2002-08-14 Procter & Gamble Novel 2-decarboxy-2-phosphinico prostaglandin f analogs
JP2003518998A (ja) 1999-12-30 2003-06-17 ザ プロクター アンド ギャンブル カンパニー 生分解性プラスチック製の食品提供用物品
US6548535B2 (en) 2000-01-18 2003-04-15 Merck & Co., Inc. Method for treating ocular hypertension
IL143477A (en) 2001-05-31 2009-07-20 Finetech Pharmaceutical Ltd Process for the preparation of 17-phenyl-18,19,20-trinor-pgf2?? and its derivatives
AU4466901A (en) * 2000-03-31 2001-10-08 Toray Industries, Inc. Hair growth or hair formation controlling agents
US20020146439A1 (en) 2000-03-31 2002-10-10 Delong Mitchell Anthony Compositions and methods for treating hair loss using oximyl and hydroxylamino prostaglandins
US20020037914A1 (en) 2000-03-31 2002-03-28 Delong Mitchell Anthony Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins
US20020172693A1 (en) 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
FR2812191B1 (fr) 2000-07-28 2003-10-17 Oreal Utilisation d'agonistes du recepteur des prostaglandines e2 (ep-3) pour attenuer, diminuer ou stopper la pousse des cheveux et des poils dans des preparations cosmetiques
FR2812193B1 (fr) 2000-07-28 2003-10-24 Oreal Utilisation d'antagoniste des recepteurs des prostaglandines ep-2 et/ou ep-4 pour attenuer, diminuer ou stopper la pousse des cheveux et des poils dans des preparations cosmetiques
FR2812190B1 (fr) * 2000-07-28 2003-01-31 Oreal Utilisation d'agonistes non prostanoiques des recepteurs des prostaglandines ep-2 et/ou ep-4 comme agent cosmetique permettant d'attenuer, de diminuer ou d'arreter la chute des cheveux et des poils
EP1298223A3 (de) 2001-09-28 2003-07-23 Pfizer Products Inc. Methoden die mit der A-C Wiederholungs-Z-Sequenz stromaufwärts des Aldosereduktasegens in Zusammenhang stehen
US20040082013A1 (en) 2002-01-24 2004-04-29 Regan John W Methods for screening for substances which inhibit fp prostanoid receptor interaction with a compound having pgf2alpha activity and methods of treating cancer
US7351404B2 (en) 2002-02-04 2008-04-01 Allergan, Inc. Method of enhancing hair growth
US7186707B2 (en) 2002-04-01 2007-03-06 University Of Florida Prodrugs for use as ophthalmic agents
GB0208785D0 (en) 2002-04-17 2002-05-29 Medical Res Council Treatment methtods
US7320967B2 (en) * 2002-04-23 2008-01-22 L'oreal Cosmetic composition, method of cosmetic treatment and preparation of a composition for promoting the growth and/or preventing or delaying the loss of hair
US6573294B1 (en) 2002-05-14 2003-06-03 Allergan, Inc. 8-azaprostaglandin analogs as agents for lowering intraocular pressure
US7521530B2 (en) 2002-06-11 2009-04-21 Universite De Montreal Peptides and peptidomimetics useful for inhibiting the activity of prostaglandin F2α receptor
US20030199590A1 (en) 2002-07-25 2003-10-23 Cagle Gerald D Prostaglandin analogues for promotion of hair growth
JP4300833B2 (ja) 2003-03-17 2009-07-22 ソニー株式会社 半導体発光素子の製造方法
US7589233B2 (en) 2003-07-29 2009-09-15 Signature R&D Holdings, Llc L-Threonine derivatives of high therapeutic index
US7045634B2 (en) 2003-09-05 2006-05-16 Allergan, Inc. Prostamide receptor antagonists
US20050058614A1 (en) * 2003-09-15 2005-03-17 Allergan, Inc. Methods for the treatment of gray hair using cyclopentane(ene) heptan(en)oic acid amides
US7070768B2 (en) * 2003-09-25 2006-07-04 Allergan, Inc. Method for imparting artificial tan to human skin
US20050112075A1 (en) 2003-11-25 2005-05-26 Hwang Cheng S. Reduction of hair growth
JP2007512347A (ja) 2003-11-26 2007-05-17 デューク・ユニバーシティー 緑内障を予防するかまたは治療する方法
US7288029B1 (en) 2005-01-19 2007-10-30 Gkn Driveline North America, Inc. Propshaft with crash-worthiness
US20060135609A1 (en) 2004-10-21 2006-06-22 Duke University Ophthamological drugs
GB0506759D0 (en) 2005-04-02 2005-05-11 Medical Res Council Combination treatment methods
WO2007123818A2 (en) 2006-04-18 2007-11-01 Nitromed, Inc. Organic nitric oxide enhancing salts of prostaglandins, compositions and methods of use
WO2007125818A1 (ja) 2006-04-24 2007-11-08 Jsr Corporation 重合体及びそれを含有する感光性樹脂組成物
US20070254920A1 (en) 2006-04-26 2007-11-01 Aerie Pharmaceuticals, Inc. Prodrug derivatives of acids using alcohols with homotopic hydroxy groups and methods for their preparation and use
US7868032B2 (en) 2006-10-18 2011-01-11 Allergan, Inc. Prostamide receptor antagonists
JP5095269B2 (ja) 2007-06-05 2012-12-12 北海道エア・ウォーター株式会社 通信システム
US20090018204A1 (en) 2007-07-13 2009-01-15 Brinkenhoff Michael C Composition and method for enhancing hair growth
JP2012507552A (ja) 2008-10-29 2012-03-29 アエリエ・ファーマシューティカルズ・インコーポレーテッド プロスタグラジンのアミノ酸塩
US8623918B2 (en) 2008-10-29 2014-01-07 Novaer Holdings, Inc. Amino acid salts of prostaglandins
US8722739B2 (en) 2008-10-29 2014-05-13 Novaer Holdings, Inc. Amino acid salts of prostaglandins
WO2010108012A1 (en) 2009-03-18 2010-09-23 Duke University Compositions and methods for promoting nasal patency and treating neurogenic bladder using prostaglandins
JP5331025B2 (ja) 2010-02-18 2013-10-30 八千代工業株式会社 サンルーフ装置のガイドパイプの保持構造

Also Published As

Publication number Publication date
DE60115869T2 (de) 2006-07-06
CN1206976C (zh) 2005-06-22
US20080241078A1 (en) 2008-10-02
EP1267803A2 (de) 2003-01-02
WO2001074313A3 (en) 2002-02-21
CA2401718A1 (en) 2001-10-11
CA2401718C (en) 2007-05-29
JP5579158B2 (ja) 2014-08-27
US20070092466A1 (en) 2007-04-26
JP2003528897A (ja) 2003-09-30
CN1419437A (zh) 2003-05-21
EP1267803B1 (de) 2005-12-14
AU2001251166A1 (en) 2001-10-15
DE60115869D1 (de) 2006-01-19
WO2001074313A2 (en) 2001-10-11
US8618086B2 (en) 2013-12-31
JP2012046545A (ja) 2012-03-08
US7407987B2 (en) 2008-08-05
US20020037914A1 (en) 2002-03-28
ES2254395T3 (es) 2006-06-16

Similar Documents

Publication Publication Date Title
DE60115869D1 (de) Zusammenseztungen und verfahren zur behandlung von haarausfall unter verwendung von c16-c20 aromatischen tetrahydro-prostaglandinen
DE60115000D1 (de) Die Verwendung von Prostaglandin F Analoga zur Herstellung von Zusammensetzungen für die Behandlung von Haarausfall.
WO2001074307A3 (en) Compositions and methods for treating hair loss using oximyl- and hydroxylamino- prostaglandins
AU2001253038A1 (en) Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
NO20016055L (no) Splitteanordning for murblokker med fremspring i n¶rheten av splitteblader
ATE371475T1 (de) Methoden zur behandlung der hautpigmentierung
EE9700225A (et) Meetod diabetes mellituse raviks, kasutades KKF
DE60308212D1 (de) Verwendung von celluloseperlen zur mattierung der haut
ATE438337T1 (de) Verfahren zum auswerten neuer gehirnschlagsbehandlungen unter verwendung einer geweberisikokarte
DE60141706D1 (de) Verbindungen mit fungizider wirkung und verfahren zur ihrer herstellung und verwendung
ATE245416T1 (de) Neue fettanaloge zur behandlung von diabetes
ATE336242T1 (de) Verwendung von gaboxadol zur behandlung von premenstruelle störung, postnatal depression oder postmenopausal-bedingte-dysphorische störung
DE60319398D1 (de) Verfahren zur herstellung einer pureezusammensetzung enthaltend eine stabilisierte fruchtmarkzusammensetzung
BR0008239A (pt) Processo de redução de crescimento de cabelos em mamìferos, uso de um inibidor de proteìna-tirosina quinase, processo de produção de uma composição para inibir o crescimento de cabelo de mamìferos, e, composição usada para inibir crescimento de cabelo em mamìferos
DE60130661D1 (de) Verwendung der 13-cis retinsäure zur behandlung von emphysemen
PT1075284E (pt) Uso de um corante vital para facilitar as intervencoes cirurgicas em cirurgia vitreo-retiniana
ATE473729T1 (de) Verfahren zur behandlung von rosacea und telangiectasia
DE69829202D1 (de) Verwendung von mirtazapine zur herstellung eines medikaments zur behandlung von schlafapnoen
DE50010007D1 (de) Verfahren zur herstellung von wasserstoffperoxid
DE60318342D1 (de) Verwendung eines Granatapfelbaumextrakts zur Erhaltung der Haarfarbe
DE60002529D1 (de) Verfahren zur herstellung von wasserstoffperoxid
ATE451091T1 (de) Kosmetisches peeling-verfahren unter verwendung von harnstoff
ATE370103T1 (de) Verfahren zur behandlung von schlamm
ATE270542T1 (de) Zusammensetzung zur verhinderung der keimbindung
ATE260029T1 (de) Verwendung von anionischen tensiden in heissschäumen zur entfernung von unerwünschten pflanzen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties